What is it about?
This article is about "A clinical trial of ONO-4053 in patients with seasonal allergic rhinitis". We demonstrated that the efficacy of ONO-4053 was greater than that of pranlukast with a similar safety profile. This study indicates the potential of ONO-4053 for use as a treatment for seasonal allergic rhinitis.
Featured Image
Why is it important?
The efficacy of ONO-4053 was demonstrated for all symptoms of allergic rhinitis, including sneezing, rhinorrhea, nasal itching, and nasal obstruction. ONO-4053 has the potential to become a new class of therapeutic agent that can be used to treat any symptom of allergic rhinitis.
Perspectives
This is the first article that indicates the DP1 antagonist is effective on symptoms of allergic rhinitis and is more effective than leukotriene receptor antagonist. We found ONO-4053 has not only DP1 antagonistic reaction but also has inhibitory effect on mast cell degranulation. I think this results indicate not only the appearance of new therapeutic regimen but also the new target for controlling allergic rhinitis.
Hajime Yamamotoya
Ono Yakuhin Kogyo Kabushiki Kaisha
Read the Original
This page is a summary of: A randomized controlled phase II clinical trial comparing ONO-4053, a novel DP1 antagonist, with a leukotriene receptor antagonist pranlukast in patients with seasonal allergic rhinitis, Allergy, May 2017, Wiley,
DOI: 10.1111/all.13174.
You can read the full text:
Contributors
The following have contributed to this page
